Skin micro-injector

Bold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

Needle-based injections are very common in modern medicine, notably in ongoing vaccination efforts worldwide. However, needle phobia and infection risks affect patient compliance with medical treatments, while millions of used needles contaminate the environment.

Challenges in Injection Methods

Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. Thus, new minimal-invasive procedures are needed.

Jet Injectors Overview

Jet injectors are needle-free medical devices that pressurize thin liquid filaments to penetrate the skin. Jet injections have been effective in subcutaneous and intramuscular delivery, ex vivo, and in vivo.

Limitations of Current Jet Injection Methods

However, the expected needle-free revolution for medical treatments has neither been fulfilled nor widely commercialized due to factors such as:

  1. Bruising, a painful consequence of delivering large volumes in a single location.
  2. When using wrong energy settings, or misalignment with respect to the skin, the injected liquid can perfuse other layers.
  3. The rejected liquid splashes back, leading to incorrect dose delivery, risks of cross-contamination of the injector parts, or splash-back on the caregiver.
  4. Commercial jet injection methods, such as springs or compressed gas, are noisy which can distress the patient.

The Bold-Jet Solution

Hence, there is a need to develop a new way to deliver smaller doses with maximum accuracy in targeting specific skin layers. Bold-Jet is aimed at revolutionizing the experience of people who receive or perform frequent injections by developing, for the first time, a needle-free device using microjets that is safer, minimally invasive, and eco-friendly.

Benefits of Bold-Jet

By avoiding the use of needles, we can increase adherence to treatments by patients with fear of sharps and expand clinical routes for existing drugs and treatments.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-6-2022
Einddatum30-11-2023
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • UNIVERSITEIT TWENTEpenvoerder

Land(en)

Geen landeninformatie beschikbaar

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

EIC Transition

Integrated needle-free injection and sensing using opto-microfluidics

iSENS is developing BoldJet, a portable needle-free injector using thermocavitation microjets for precise, safe, and environmentally friendly medication delivery, enhancing patient compliance and healthcare outcomes.

€ 2.499.999
EIC Accelerator

AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant

AmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health.

€ 1.389.062
MIT Haalbaarheid

Intravitreal Injector

De IDE Group ontwikkelt een gebruiksvriendelijke intravitreal injector voor maculadegeneratie, waardoor de behandeling eenvoudiger, minder intimiderend en kosteneffectiever wordt.

€ 20.000
MIT Haalbaarheid

Dermaal microinjectie systeem met holle micronaalden voor oa vaccinaties

Dit project onderzoekt de haalbaarheid van een pijnloos micro-injectiesysteem voor nauwkeurige medicatietoediening, met potentieel voor kankervaccinaties en verbeterde vaccinatiecapaciteit.

€ 20.000